← The Wire
IMNMNasdaq
Immunome Inc.
Pharmaceutical Preparations · DE · CIK 1472012
Develops targeted oncology therapies, including antibody-drug conjugates, to improve cancer patient outcomes
$2.08B
Market cap
$21.04
Last close
+5.4%
1D
+9.7%
5D
1.6M
Volume
Price · last 39 sessions-9.8%
May 4L $17.91 · H $23.33Jun 29
150
Total filings
Jun 12, 2026
Last filing
12/31
Fiscal year end
8-KShareholder VoteJun 12, 202610-Q10-QMay 12, 20268-KResults of OperationsMay 12, 2026DEFA14ADEFA14AApr 24, 2026DEF 14ADEF 14AApr 24, 202610-K10-KMar 3, 20268-KResults of OperationsMar 3, 2026SC 13D/ASC 13D/ADec 22, 20258-KCompany UpdateDec 17, 2025424B5424B5Dec 17, 2025424B5424B5Dec 15, 20258-KReg FD Disclosure · Company UpdateDec 15, 202510-Q10-QNov 6, 20258-KResults of OperationsNov 6, 202510-Q10-QAug 6, 20258-KResults of OperationsAug 6, 20258-KShareholder VoteJun 11, 202510-Q10-QMay 12, 20258-KResults of Operations · Company UpdateMay 12, 2025DEFA14ADEFA14AApr 24, 2025DEF 14ADEF 14AApr 24, 202510-K10-KMar 19, 20258-KResults of OperationsMar 19, 20258-KCompany UpdateJan 30, 2025424B5424B5Jan 30, 2025424B5424B5Jan 29, 20258-KResults of Operations · Company UpdateJan 29, 20258-KExecutive ChangeJan 23, 2025SC 13GSC 13GNov 14, 202410-Q10-QNov 13, 20248-KResults of OperationsNov 13, 2024SC 13GSC 13GNov 8, 20248-KMaterial Agreement · Agreement TerminatedOct 29, 2024SC 13GSC 13GOct 22, 20248-KCompany UpdateOct 8, 202410-Q10-QAug 12, 20248-KResults of OperationsAug 12, 20248-KShareholder VoteJun 13, 2024424B5424B5May 14, 202410-Q10-QMay 14, 20248-KResults of OperationsMay 14, 20248-KExecutive ChangeApr 30, 2024DEFA14ADEFA14AApr 26, 2024DEF 14ADEF 14AApr 26, 20248-KExecutive ChangeApr 25, 202410-K10-KMar 28, 20248-KResults of OperationsMar 28, 20248-KMaterial Agreement · Acquisition / DispositionMar 26, 20248-KCompany UpdateFeb 14, 2024424B5424B5Feb 14, 2024424B5424B5Feb 13, 20248-KResults of Operations · Company UpdateFeb 13, 2024SC 13GSC 13GFeb 9, 20248-KMaterial Agreement · Equity IssuanceFeb 6, 20248-KExecutive ChangeFeb 1, 20248-KReg FD DisclosureJan 11, 20248-KMaterial Agreement · Equity IssuanceJan 8, 20248-KExecutive ChangeJan 2, 20248-KExecutive ChangeDec 29, 20238-KCompany UpdateDec 26, 20238-K/ACompany UpdateNov 22, 20238-KReg FD DisclosureNov 15, 20238-KResults of OperationsNov 9, 202310-Q10-QNov 9, 20238-KExecutive ChangeNov 8, 2023SC 13GSC 13GOct 12, 2023SC 13DSC 13DOct 12, 2023SC 13DSC 13DOct 12, 2023SC 13GSC 13GOct 12, 20238-KExecutive Change · Material AgreementOct 4, 2023425425Sep 21, 20238-KCompany UpdateSep 21, 20238-KResults of OperationsAug 9, 202310-Q10-QAug 9, 2023S-4S-4Aug 8, 2023SC 13DSC 13DJul 7, 2023425425Jul 5, 20238-KCompany UpdateJul 5, 2023425425Jun 29, 2023425425Jun 29, 2023
Insider Activity
◆ Cluster Buy · 2 insidersIn the 90 days to Mar 27, 2026: 2 insiders bought $644K · 1 sold $1.3M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 27, 2026 | Siegall Clay BPresident and CEO | Buy | 25,450 | $19.67 | $501K |
| Mar 23, 2026 | Wagenheim PhilipDirector | Sell | 28,200 | $20.65 | $582K |
| Mar 20, 2026 | Wagenheim PhilipDirector | Sell | 36,800 | $20.47 | $753K |
| Mar 11, 2026 | Bienaime Jean JacquesDirector | Buy | 1,000 | $21.55 | $22K |
| Mar 10, 2026 | Bienaime Jean JacquesDirector | Buy | 1,000 | $22.12 | $22K |
| Dec 30, 2025 | Siegall Clay BPresident and CEO | Buy | 4,729 | $21.15 | $100K |
| Dec 22, 2025 | Barchas IsaacDirector | Sell | 371,949 | $21.72 | $8.1M |
| Dec 22, 2025 | Barchas IsaacDirector | Sell | 11,251 | $22.34 | $251K |
| Dec 19, 2025 | Tsai PhilipChief Technical Officer | Buy | 10,000 | $20.49 | $205K |
| Dec 19, 2025 | Siegall Clay BPresident and CEO | Buy | 7,278 | $20.48 | $149K |
| Dec 18, 2025 | Siegall Clay BPresident and CEO | Buy | 46,511 | $21.50 | $1000K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance